NCT04109963 (TRIC-VCI) is a Phase 2 clinical trial of Remote ischemic conditioning in Vascular Dementia, sponsored by University of Calgary.

Who is sponsoring NCT04109963?

NCT04109963 is sponsored by University of Calgary.

What drugs are being tested in NCT04109963?

Interventions in NCT04109963: Remote ischemic conditioning.

What condition does NCT04109963 study?

NCT04109963 studies Vascular Dementia, Cerebral Small Vessel Diseases, Cerebral Small Vessel Ischaemic Disease, Vascular Cognitive Impairment.

Is NCT04109963 still recruiting?

NCT04109963 is currently status unknown. Last updated 9 June 2022.

Last reviewed 2022-06-09 · How we verify

NCT04109963: TRIC-VCI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment

Status unknown Phase 2 Last updated 9 June 2022

What this trial tests

Phase 2 trial testing Remote ischemic conditioning in Vascular Dementia in 24 participants. Status unknown.

Timeline

26 September 2019

Primary endpoint
31 December 2022

1 March 2023

Quick facts

Lead sponsor	University of Calgary
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	24
Start date	26 September 2019
Primary completion	31 December 2022
Estimated completion	1 March 2023
Sites	1 location across Canada

Drugs / interventions tested

Remote ischemic conditioning

Conditions studied

Vascular Dementia — all drugs for Vascular Dementia →
Cerebral Small Vessel Diseases — all drugs for Cerebral Small Vessel Diseases →
Cerebral Small Vessel Ischaemic Disease — all drugs for Cerebral Small Vessel Ischaemic Disease →
Vascular Cognitive Impairment — all drugs for Vascular Cognitive Impairment →

Sponsor

University of Calgary

Who can join

Adults 60 to 85, any sex, with Vascular Dementia or Cerebral Small Vessel Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cerebral small vessel disease is a common cause of cognitive impairment. Remote ischemic pre-conditioning (RIC) is a technique to induce brief periods of limb ischemia-reperfusion that is hypothesized to increase tolerance of the brain to hypoperfusion and increase cerebral blood flow. Patients with cognitive impairment, preserved basic activities of daily living, and brain computed tomography (CT) or magnetic resonance imaging (MRI) evidence of confluent white matter hyperintensities or multiple brain infarcts will be randomized to either RIC performed once a day on one arm, or twice per day on one arm, for 30 days, to test tolerability and effects on MRI markers of blood flow.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Trial of remote ischaemic preconditioning in vascular cognitive impairment (TRIC-VCI): protocol.
Ganesh A, Barber P, Black SE, Corbett D, et al · · 2020 · cited 12× · PMID 33055122 · DOI 10.1136/bmjopen-2020-040466
Remote ischaemic conditioning for neurological disorders-a systematic review and narrative synthesis.
Alhashimi A, Kamarova M, Baig SS, Nair KPS, et al · · 2024 · cited 5× · PMID 39702489 · DOI 10.1186/s13643-024-02725-8
The future of biomarkers for vascular contributions to cognitive impairment and dementia (VCID): proceedings of the 2025 annual workshop of the Albert research institute for white matter and cognition.
Lennon MJ, Karvelas N, Ganesh A, Whitehead S, et al · · 2025 · cited 3× · PMID 40542975 · DOI 10.1007/s11357-025-01746-y
Advancing clinical trial readiness in white matter disease and related dementias: key steps for future research progress.
Sompol P, Jicha GA, Hinman JD, Brickman AM, et al · · 2026 · PMID 40690160 · DOI 10.1007/s11357-025-01805-4
Remote Ischaemic Conditioning for Neurological Disorders – A Systematic Review and Narrative Synthesis
Alhashimi A, Kamarova M, B S, Nair KS, et al · · 2024 · DOI 10.21203/rs.3.rs-3974093/v1

Verify or expand the search:

Other trials of Remote ischemic conditioning

Trials testing the same drug.

NCT03484936 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage · NA · not yet recruiting
NCT07412249 — Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis · NA · recruiting
NCT03669653 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke · NA · not yet recruiting
NCT06702644 — Safety and Efficacy of Remote Ischemic Conditioning in Patients with Chronic Internal Carotid Artery Occlusion Receiving · NA · not yet recruiting
NCT06171334 — Remote Ischemic Conditioning in PPMS · NA · not yet recruiting

Other recruiting trials for Vascular Dementia

Currently open trials in the same condition.

NCT07149038 — Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment · NA · recruiting
NCT06298474 — The BRAIN App (Phase 2 SBIR) · NA · recruiting
NCT06862557 — Pulsed Electromagnetic Field Treatment With Dementia Patients · NA · recruiting
NCT06416371 — Retinal Vessel Leakage in Cerebral Small Vessel Disease · recruiting
NCT07259499 — Predictors of Emergency Department Use in Frail Patients · recruiting

Other University of Calgary trials

Trials by the same sponsor.

NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04109963 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Calgary
Last refreshed: 9 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04109963.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing